CAS: 10305-73-4; (R)-2,3-Dihydro-1H-Inden-1-Amine Hydrochloride

该化合物是一种具有立体化学定义(R)配置的手感导剂,使其成为非对称合成和制药应用中有价值的中间体,其内氧脚架具有结构僵硬性,加强了对手艺识别和皮带设计的选择性,盐状确保了处理和储存的稳定性和溶解性,该化合物因其定义明确,具有立体化学和功能组的兼容性,对对应选择性催化剂,生物活性分子和受体定向物剂的开发特别有用,可满足严格的研究和工业要求,支持合成和药用化学工作流程的再生.

英文名称(R)-2,3-Dihydro-1H-Inden-1-Amine Hydrochloride
中文名称(R)-1-氨基茚盐酸盐
IUPAC名称(R)-2,3-dihydro-1H-inden-1-amine hydrochloride
其它别名(R)-(-)-1-氨基茚满盐酸盐; (1R)-Indan-1-Amine Hydrochloride
CAS编号10305-73-4
MFCD编号:MFCD11100854
EINECS号:692-843-1
FDA UNII编号:79Z3N398K9
分子式:C9H12ClN
分子量:169.65
产品CID: 64030
产品分类有机原料→分子砌块→芳环类化合物→苯类化合物

相似结构搜索
产品信息参考;;;;
InChIKey: RHAAGWRBIVCBSY-SBSPUUFOSA-N
InChI=1S/C9H11N.ClH/c10-9-6-5-7-3-1-2-4-8(7)9;/h1-4,9H,5-6,10H2;1H/t9-;/m1./s1…
计算化学: 氢键受体数1.0氢键供体数1.0可旋转键数0.0

相似化合物

10277-74-4 34698-41-4 70146-15-5

MSDS等安全信息

GHS象形图
GHS符号GHS07 & GHS09;
注释: Exclamation mark & Environment
危险类别特定目标器官毒性 - 单次接触类别3
皮肤腐蚀/刺激类别2
严重眼刺激类别2
水生慢性毒性类别2
严重眼刺激类别2A
警示词Warning(警告)
危险描述H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
H411 |对水生生物有毒并具有长期持续影响.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
危险品标志Xi
安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body

欧盟法规

C&L通报

合成工艺路线路线简述

(R)-(-)-1-氨基茚满置于盐酸体系中,用异丙醇用作溶剂,化学反应 0.5H,以84.5%的收率获得(R)-(-)-1-氨基茚盐酸盐
参考文献: Process For The Preparation Of Enatiomerically Pure 1-Aminoindan[fr] Procédé De Préparation De 1-Aminoindane énantiomériquement Pur
标题: Process For The Preparation Of Enatiomerically Pure 1-Aminoindan[fr] Procédé De Préparation De 1-Aminoindane énantiomériquement Pur
摘要:本发明涉及一种通过使用n-乙酰-L-谷氨酸作为分离剂对1-氨基茚进行对映异构分离,制备光学纯(R)-1-氨基茚的方法.另一方面,本发明涉及(R)-1-氨基茚与n-乙酰-L-谷氨酸的对映异构盐,以及它们在制备拉沙吉林的过程中的应用.

专利信息

专利号:US-8188113-B2
优先权日:2006-09-14
标题 :Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C; DECIPHERA PHARMACEUTICALS INC
摘要:The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.